Table of Contents

Ozempic does not come in pill form. It is only available as a weekly injection. However, the same active ingredient, semaglutide, is available in tablet form through other medications, including Rybelsus and newer oral GLP-1 treatments developed for weight loss.

So, how do they compare to Ozempic injections?

Below, we’ll explain how semaglutide tablets work and what options are currently available for people who prefer oral weight-loss medications.

Key Takeaways

  • Ozempic only comes in a once-weekly injection format.
  • There are oral semaglutide tablets. Rybelsus is an oral version of semaglutide approved for diabetes management, and Wegovy tablets are a new high-dose semaglutide pill approved for weight management. These pills are sometimes nicknamed “Ozempic pills,” but they are different products with their own dosing rules.
  • Wegovy tablets produce significant weight loss. In the OASIS 4 trial, daily oral semaglutide 25 mg (Wegovy pill) produced about 14% average weight loss and up to 16.6% when people stayed on treatment.
  • Side effects are similar across shots and pills. Nausea, vomiting, diarrhoea, and stomach discomfort are common in both injections and pills.
  • There are other weight-loss pills. Medications such as Contrave, Qsymia, phentermine, and orlistat are available and may suit people who cannot use semaglutide.

Does Ozempic come in pill form?

No. Ozempic does not come in a pill form for weight loss or diabetes. It’s only available as a pre-filled pen that you inject under the skin once a week. Ozempic pens are available in several strengths (0.25 mg, 0.5 mg, 1 mg, and 2 mg) for gradual dose escalation.

If you’re looking for an Ozempic-like pill, Rybelsus is the closest available option. Rybelsus is essentially oral semaglutide, which is the first pill form of a GLP-1 agonist approved by the FDA. It hit the market in 2019 for type 2 diabetes management.

Many people refer to it as the “Ozempic pill” because it’s the same active ingredient (semaglutide) made by the same company (Novo Nordisk), just delivered in tablet form instead of an injection.

How oral semaglutide works

Delivering a large peptide like semaglutide by mouth is challenging because it is destroyed in the stomach. To overcome this, Rybelsus and Wegovy tablets contain salcaprozate sodium (SNAC).

SNAC helps the body absorb semaglutide in four main ways:

  • It briefly raises stomach pH where the tablet dissolves. As the tablet breaks down, SNAC temporarily makes the surrounding stomach environment less acidic. This slows the activity of pepsin, an enzyme that normally breaks down proteins. With less active pepsin, semaglutide is less likely to be destroyed.
  • It helps keep semaglutide stable. Semaglutide molecules can clump together in acidic conditions. SNAC alters the local chemical environment so the molecules remain separated, making them easier for the body to absorb.
  • It temporarily increases absorption through the stomach lining. SNAC briefly interacts with the stomach lining and makes the cell membranes more flexible. This creates a short window during which semaglutide can pass through the stomach wall and enter the bloodstream.
  • Its effects are temporary. SNAC does not permanently change the stomach lining. Once it is absorbed and cleared from the body, the stomach cells return to normal.

Are there weight loss pills like Ozempic?

Yes. In late 2025, the FDA approved an oral version of Wegovy, which is a 25 mg semaglutide pill for chronic weight management. This decision made Wegovy pill the first oral GLP-1 medication for weight loss in the US. The product launched in early January 2026. Many people refer to it as a “Wegovy pill” or “oral Wegovy.”

Semaglutide injections vs. pills for weight loss

Current evidence suggests that injections still produce greater weight loss, although oral formulations are beginning to narrow the gap.

Wegovy is semaglutide at 2.4 mg weekly, approved for obesity. It’s very effective, about 15% average body weight loss in 15 months according to the pivotal trial. Many participants lost even more (20% or more), especially if they stayed on it the whole time.

Clinical trial results (OASIS-4 trial) of the Wegovy pill (25 mg) showed that this high-dose pill can yield comparable weight loss to the Wegovy injections. Over ~64 weeks, participants on the 25 mg pill lost about 14% of their starting weight on average, and up to 17% if you count only those who adhered to treatment fully.

That’s essentially on par with the 15% from the injectable. This is a huge development, and patients may soon have a true “Ozempic pill” alternative for weight loss.

Side effects of Ozempic-like pills

No matter which form of semaglutide you take, the side effect profile is generally similar because both forms work through the same biological pathways in the body.

The main difference is that injections can cause local injection-site reactions, such as redness or irritation where the needle is inserted. Pills, on the other hand, avoid these reactions because they are taken orally. Aside from that, most side effects are comparable.

These include:

    • Nausea – this is the #1 most frequent side effect. Many people feel queasy, especially when first starting or when the dose is increased. It often improves over time as your body adjusts. Taking your time to eat slowly and not overeating can help, since the drug is slowing your digestion.
    • Vomiting – related to the nausea, some people throw up if the nausea is strong. Staying hydrated is important if this happens.
    • Diarrhea – semaglutide can affect gut motility, sometimes causing diarrhea in the adjustment phase.
    • Stomach pain – mild abdominal discomfort or bloating can occur, since food is staying longer in your stomach.
    • Constipation or indigestion – some experience slower bowel movements or heartburn. Interestingly, you see both diarrhea and constipation reported, which just means any GI change is possible.

These side effects are usually mild to moderate and tend to ease up as you continue the medication. In fact, the dose-escalation schedule (gradually raising the dose) is designed to minimize these issues.

If you find nausea troublesome, your doctor might keep you at a lower dose longer or suggest dietary adjustments. There are also anti-nausea medications like ondansetron that can be used if needed.

Other weight loss pills and alternatives to consider

If you prefer a pill and semaglutide is not suitable, several other FDA?approved weight?loss medications may help. Each works differently and has its own pros and cons.

1. Orlistat (Alli, Xenical)

This is a weight loss pill that works in your gut to prevent about 30% of the fat you eat from being absorbed. The excess fat exits your body in stools. It’s the only OTC weight loss aid that’s FDA-approved.

Weight loss with orlistat often begins within about two weeks after starting treatment, with significant reductions typically seen after two months. By the end of six months, patients taking orlistat lose an average of about 5.6 kg (12.3 lbs), compared with roughly 2.4 kg (5.3 lbs) in those taking a placebo.

Its side effects are mainly gastrointestinal, such as oily, fatty stools, urgency, and gas, especially if you eat high-fat meals. It encourages you to stick to a low-fat diet to avoid those unpleasant effects.

Orlistat can also reduce the absorption of fat-soluble vitamins, so a multivitamin is recommended. It’s a safe option for a small boost in weight loss, but not nearly as powerful as GLP-1 drugs or newer agents.

2. Phentermine (Adipex-P)

Phentermine is an older appetite suppressant and stimulant approved for short-term use (up to 12 weeks). It is taken as a daily pill and works by stimulating the central nervous system to reduce hunger and help people eat less.

It can help jump-start weight loss, with typical results of about 5% of body weight over three months. It is relatively inexpensive and widely prescribed, but it is not intended for long-term use because of the potential for dependence and side effects such as increased heart rate, higher blood pressure, insomnia, and jitteriness.

Some research suggests longer use may provide additional benefits. One study found that people who used phentermine for more than 12 months lost 7.4% more weight than those who stopped after three months, without an increased risk of cardiovascular problems.

Another study reported that nearly 40% of initial non-responders achieved meaningful weight loss by six months, with no major cardiovascular risks observed.

Because phentermine is generally prescribed only for short-term treatment, weight regain can occur after stopping the medication unless healthy lifestyle changes are maintained.

3. Phentermine/Topiramate (Qsymia)

This is a combo of low-dose phentermine and topiramate, which is a seizure/migraine medication that also curbs appetite. Qsymia is a daily capsule approved for long-term use in obesity. It’s more effective than phentermine alone.

In one study, the combination of phentermine and topiramate led to a 4.1% reduction in body weight after 20 weeks, compared with 3.6% with phentermine alone.

A meta-analysis comparing phentermine-topiramate with other weight-loss medications found it had the highest success rate, with about 75% of participants achieving at least 5% weight loss. After one year of treatment, users lost an average of 19.4 lbs (8.8 kg).

Side effects can include:

    • tingling in fingers/toes
    • dizziness
    • taste changes
    • insomnia
    • dry mouth
    • constipation

Topiramate can cause birth defects, so women must use birth control and have monthly pregnancy tests on Qsymia. It’s a controlled substance (due to phentermine), but it’s an effective option for many.

4. Bupropion/Naltrexone (Contrave)

Bupropion helps reduce hunger and increase energy expenditure by boosting certain brain chemicals involved in appetite and metabolism. However, it can also trigger a natural response in the body that gradually weakens this effect. Naltrexone, the other ingredient in Contrave, blocks this response, allowing bupropion to continue supporting weight loss.

In a real-world study, patients taking Contrave (naltrexone/bupropion) achieved an average reduction of 9.2% after six months and 9.7% after 12 months.

A review of 14 studies also highlighted the potential of the naltrexone-bupropion combination to address behavioral and psychological factors linked to obesity, including binge eating and emotional eating.

In one study, participants with moderate to severe binge eating symptoms began to show improvement as early as week four. By week 24, about 83% reported little to no binge eating problems.

It’s not as potent as GLP-1 agonists, but it helps some people significantly, especially those who struggle with food cravings or emotional eating.

Common side effects include:

    • nausea
    • headache
    • constipation
    • diarrhea
    • insomnia

It should not be used in people with uncontrolled high blood pressure or seizure disorders (due to bupropion). Also, because naltrexone blocks opioid receptors, you can’t be on opioid pain meds while on Contrave.

Bottom line

Ozempic itself is available only as a weekly injection. However, the same active ingredient, semaglutide, is also available in pill form, sold as Rybelsus tablets for diabetes and Wegovy tablets for weight management. If semaglutide isn’t right for you, there are other weight loss pills and treatments (Contrave, Qsymia, orlistat, etc.) that you can consider with your healthcare provider.

Frequently Asked Questions

No. Ozempic is only available as a once-weekly injection. However, semaglutide, the same active ingredient, now also comes in tablet form as Wegovy tablets for weight loss and Rybelsus tablets for type 2 diabetes.

Yes. The Wegovy pill contains semaglutide, the same drug used in Ozempic, and works by activating GLP-1 receptors to reduce appetite and improve blood sugar control. Another oral semaglutide product, Rybelsus, works similarly but is mainly prescribed for diabetes.

There is no “Ozempic pill,” but the oral version of semaglutide sold as Wegovy tablets is approved for weight loss. Studies show people taking the pill along with diet and exercise lost about 14% of their starting weight on average.

In most studies, injectable Ozempic leads to greater weight loss than oral Rybelsus. The injection allows higher effective doses of semaglutide in the bloodstream.

No. Rybelsus 7 mg is not directly equivalent to any dose of Ozempic. Because the pill and injection are absorbed differently, doctors do not convert their doses on a milligram-to-milligram basis.

Injectable Ozempic usually produces greater weight loss than lower-dose semaglutide tablets such as Rybelsus. However, higher-dose oral semaglutide, marketed as Wegovy tablets, has shown weight-loss results comparable to injections in clinical trials.

No. Ozempic is simply a brand name for semaglutide. Differences in effectiveness usually come from the dose and how the drug is delivered (injection vs tablet).

Not exactly, because Ozempic is itself a brand of semaglutide. In the US, semaglutide is sold under three main brands with different uses and prices. Ozempic (diabetes injection), Rybelsus (diabetes tablet), and Wegovy (weight-loss injection or tablet). The manufacturer’s list prices are roughly $1,027.51 per month for Ozempic, $997.58 per month for Rybelsus, and $1,349.02 per month for Wegovy, making Wegovy the most expensive of the three.

Some studies show that Zepbound (tirzepatide) can lead to greater average weight loss than Ozempic. Tirzepatide targets two hormone pathways (GLP-1 and GIP), which may enhance appetite suppression and metabolic effects.

Ozempic mainly works by reducing appetite and slowing stomach emptying, which helps people eat fewer calories. It also improves insulin response and blood sugar control. Fat loss occurs indirectly because overall calorie intake decreases.

Articles you may also be interested in

Sources

Bansal, A. B., Patel, P., & Khalili, Y. A. (2024, February 14). Orlistat. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK542202/

Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022 Oct;23(5):979-994. doi: 10.1007/s11154-022-09735-8. Epub 2022 Jul 15. PMID: 35838946; PMCID: PMC9515042.

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183

Wharton, S., Lingvay, I., Bogdanski, P., Vale, R. D. D., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969

Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., Oshiro, C., Yamamoto, A., Young, D. R., & Arterburn, D. E. (2019). Safety and Effectiveness of Longer?Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity, 27(4), 591–602. https://doi.org/10.1002/oby.22430

Márquez-Cruz M, Kammar-García A, Huerta-Cruz JC, Carrasco-Portugal MDC, Barranco-Garduño LM, Rodríguez-Silverio J, Rocha González HI, Reyes-García JG. Three- and six-month efficacy and safety of phentermine in a Mexican obese population. Int J Clin Pharmacol Ther. 2021 Aug;59(8):539-548. doi: 10.5414/CP203943. PMID: 34236303; PMCID: PMC8295716.

Grabarczyk, T. R. (2017). Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 38(1), 19–28. https://doi.org/10.1002/phar.2048

Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA, 315(22), 2424. https://doi.org/10.1001/jama.2016.7602

Lui, D. T. W., Tsoi, K. H., Fong, C. H. Y., Jiang, N. S., Chow, W. S., & Yuen, M. M. A. (2024). Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience. Endocrine, 87(2), 522–529. https://doi.org/10.1007/s12020-024-04029-2

Guerdjikova, A. I., Walsh, B., Shan, K., Halseth, A. E., Dunayevich, E., & McElroy, S. L. (2017). Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in Therapy, 34(10), 2307–2315. https://doi.org/10.1007/s12325-017-0613-9